Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Lenvatinib After Atezolizumab + Bevacizumab in Unresectable or Metastatic HCC
KCT0008607Phase 2Not yet recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd.. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0008607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008607.